36. 表皮水疱症 Epidermolysis bullosa Clinical trials / Disease details
臨床試験数 : 160 / 薬物数 : 195 - (DrugBank : 47) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 124
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02654483 (ClinicalTrials.gov) | August 31, 2016 | 11/1/2016 | Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients | A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients | Epidermolysis Bullosa;Pruritus | Drug: VPD-737;Other: Placebo | Jean Yuh Tang | Epidermolysis Bullosa Research Partnership;Menlo Therapeutics Inc. | Completed | 13 Years | N/A | All | 14 | Phase 2 | United States |